Clinical Trial: An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease

U.S., Aug. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07764146) titled 'An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease' on Aug. 04.

Brief Summary: VY1706 first in human study in early Alzheimer's Disease is a multicenter dose escalation study

Study Start Date: Aug. 24

Study Type: INTERVENTIONAL

Condition: Alzheimer s Disease

Intervention: DRUG: VY1706 Low dose

Low dose

DRUG: VY1706 Mid dose

Mid Dose

DRUG: VY1706 High Dose

High dose

DEVICE: Anti-AAV9 Total Antibody (TAb) Assay

Anti-AAV9 Total Antibody (TAb) Assay

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Voyager Therapeutics

Disclaimer: Curated by HT Syndication....